Retatrutide: A Triple Threat in Obesity Treatment Retatrutide, a novel investigational drug developed by Eli Lilly and Company, represents a significant advancement in the field of weight loss
What to Expect in the First Weeks of Treatment Expect nausea and appetite changes during titration, occasional palpitations for some people, and small, measurable rises in resting pulse on monitoring
And, reduced sleep overall is linked to higher body weight, diabetes, sleep apnea, and insulin resistance
That's why we focus on comprehensive treatment: the medication jumpstarts weight loss, while lifestyle changes and metabolic improvements help maintain results
By choosing a formulation that prioritizes bioavailability, such as a liposomal delivery system, you can support your body's "master antioxidant" levels without the digestive friction